When comparing atezolizumab monotherapy and combination therapy, patients who benefited from combination therapy including PD-PR/CR, PD-SD and SD-PR/CR had significantly higher TMB, Teff density in tumor and CEA expression in cancer cells, which demonstrated their important role in predicting treatment outcomes for combination therapy. The gene discussed is CEACAM5; the disease is cancer.